TipRanks
Ocular Therapeutix (CH:0OT)
:0OT
Switzerland Market
0OT
Ocular Therapeutix
RESEARCH TOOLSreports

Ocular Therapeutix (0OT) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

0OT Analyst Ratings

Strong Buy
8Ratings
Strong Buy
8 Buy
0 Hold
0 Sell
Based on 8 analysts giving stock ratings to
Ocular
Therapeutix
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0OT Stock 12 Month Forecast

Average Price Target

―
Based on 8 Wall Street analysts offering 12 month price targets for Ocular Therapeutix in the last 3 months. The average price target is CHF21.23 with a high forecast of CHF25.74 and a low forecast of CHF14.95. The average price target represents a ― change from the last price of ―.
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
Highest Price TargetCHF25.74Average Price TargetCHF21.23Lowest Price TargetCHF14.95
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on CH:0OT
Biren Amin
Piper Sandler
Piper Sandler
CHF25.74
Buy
―
Reiterated
09/29/26
Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT), Ocular Therapeutix (NASDAQ: OCUL) and Regeneron (NASDAQ: REGN)
Needham Analyst forecast on CH:0OT
Serge Belanger
Needham
Needham
CHF14.95
Buy
―
Reiterated
09/28/26
Ocular Therapeutix: Buy Rating Reiterated as Axpaxli’s Best-in-Class Durability Supports Valuation; $18 Price Target Maintained
William Blair Analyst forecast on CH:0OT
Lachlan Hanbury Brown
William Blair
William Blair
―
Buy
―
Reiterated
09/25/26
Analyst Initiates Buy on Ocular Therapeutix, Citing Strong Ophthalmology Pipeline and Attractive Long-Term Valuation
H.C. Wainwright Analyst forecast on CH:0OT
Yi Chen
H.C. Wainwright
H.C. Wainwright
CHF20.76
Buy
―
Reiterated
09/16/26
Ocular Therapeutix: Buy Rating Reiterated on AXPAXLI Regulatory Progress and Durability Profile; Price Target Maintained at $25
Bank of America Securities Analyst forecast on CH:0OT
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
CHF22.42
Buy
―
Reiterated
09/15/26
Axpaxli’s Long-Acting Edge and Regulatory Momentum Support Unchanged $27 Price Target and Buy Rating
Clear Street Analyst forecast on CH:0OT
William Maughan
Clear Street
Clear Street
CHF23.25
Buy
―
Reiterated
08/18/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (NASDAQ: AMGN), Quince Therapeutics (NASDAQ: QNCX) and Ocular Therapeutix (NASDAQ: OCUL)
TD Cowen Analyst forecast on CH:0OT
Tara Bancroft
TD Cowen
TD Cowen
CHF16.61
Buy
―
Reiterated
08/03/26
Ocular Therapeutix Earns Buy Rating on Reduced Regulatory Risk and Strong Axpaxli NDA Visibility
RBC Capital Analyst forecast on CH:0OT
Lisa Walter
RBC Capital
RBC Capital
CHF24.91
Buy
―
Reiterated
08/03/26
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX), Ocular Therapeutix (NASDAQ: OCUL) and Arcus Biosciences (NYSE: RCUS)
Chardan Capital Analyst forecast on CH:0OT
Daniil Gataulin
Chardan Capital
Chardan Capital
CHF17.44→CHF19.1
Buy
―
Reiterated
06/25/26
Analysts Conflicted on These Healthcare Names: Repligen (NASDAQ: RGEN), Exelixis (NASDAQ: EXEL) and Ocular Therapeutix (NASDAQ: OCUL)
Robert W. Baird Analyst forecast on CH:0OT
Colleen M. Kusy
Robert W. Baird
Robert W. Baird
CHF19.93→CHF24.91
Buy
―
Reiterated
06/18/26
Ocular Therapeutix price target raised to $30 from $24 at BairdOcular Therapeutix price target raised to $30 from $24 at Baird
Citizens JMP Analyst forecast on CH:0OT
Jonathan Wolleben
Citizens JMP
Citizens JMP
―
Buy
―
Reiterated
02/17/26
Ocular Therapeutix selloff brings attractive entry point, says CitizensOcular Therapeutix selloff brings attractive entry point, says Citizens
Jefferies Analyst forecast on CH:0OT
Clara Dong
Jefferies
Jefferies
CHF23.25
Buy
―
Reiterated
02/17/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (Other OTC: SNYNF) and Ocular Therapeutix (NASDAQ: OCUL)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on CH:0OT
Biren Amin
Piper Sandler
Piper Sandler
CHF25.74
Buy
―
Reiterated
09/29/26
Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT), Ocular Therapeutix (NASDAQ: OCUL) and Regeneron (NASDAQ: REGN)
Needham Analyst forecast on CH:0OT
Serge Belanger
Needham
Needham
CHF14.95
Buy
―
Reiterated
09/28/26
Ocular Therapeutix: Buy Rating Reiterated as Axpaxli’s Best-in-Class Durability Supports Valuation; $18 Price Target Maintained
William Blair Analyst forecast on CH:0OT
Lachlan Hanbury Brown
William Blair
William Blair
―
Buy
―
Reiterated
09/25/26
Analyst Initiates Buy on Ocular Therapeutix, Citing Strong Ophthalmology Pipeline and Attractive Long-Term Valuation
H.C. Wainwright Analyst forecast on CH:0OT
Yi Chen
H.C. Wainwright
H.C. Wainwright
CHF20.76
Buy
―
Reiterated
09/16/26
Ocular Therapeutix: Buy Rating Reiterated on AXPAXLI Regulatory Progress and Durability Profile; Price Target Maintained at $25
Bank of America Securities Analyst forecast on CH:0OT
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
CHF22.42
Buy
―
Reiterated
09/15/26
Axpaxli’s Long-Acting Edge and Regulatory Momentum Support Unchanged $27 Price Target and Buy Rating
Clear Street Analyst forecast on CH:0OT
William Maughan
Clear Street
Clear Street
CHF23.25
Buy
―
Reiterated
08/18/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (NASDAQ: AMGN), Quince Therapeutics (NASDAQ: QNCX) and Ocular Therapeutix (NASDAQ: OCUL)
TD Cowen Analyst forecast on CH:0OT
Tara Bancroft
TD Cowen
TD Cowen
CHF16.61
Buy
―
Reiterated
08/03/26
Ocular Therapeutix Earns Buy Rating on Reduced Regulatory Risk and Strong Axpaxli NDA Visibility
RBC Capital Analyst forecast on CH:0OT
Lisa Walter
RBC Capital
RBC Capital
CHF24.91
Buy
―
Reiterated
08/03/26
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX), Ocular Therapeutix (NASDAQ: OCUL) and Arcus Biosciences (NYSE: RCUS)
Chardan Capital Analyst forecast on CH:0OT
Daniil Gataulin
Chardan Capital
Chardan Capital
CHF17.44→CHF19.1
Buy
―
Reiterated
06/25/26
Analysts Conflicted on These Healthcare Names: Repligen (NASDAQ: RGEN), Exelixis (NASDAQ: EXEL) and Ocular Therapeutix (NASDAQ: OCUL)
Robert W. Baird Analyst forecast on CH:0OT
Colleen M. Kusy
Robert W. Baird
Robert W. Baird
CHF19.93→CHF24.91
Buy
―
Reiterated
06/18/26
Ocular Therapeutix price target raised to $30 from $24 at BairdOcular Therapeutix price target raised to $30 from $24 at Baird
Citizens JMP Analyst forecast on CH:0OT
Jonathan Wolleben
Citizens JMP
Citizens JMP
―
Buy
―
Reiterated
02/17/26
Ocular Therapeutix selloff brings attractive entry point, says CitizensOcular Therapeutix selloff brings attractive entry point, says Citizens
Jefferies Analyst forecast on CH:0OT
Clara Dong
Jefferies
Jefferies
CHF23.25
Buy
―
Reiterated
02/17/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (Other OTC: SNYNF) and Ocular Therapeutix (NASDAQ: OCUL)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ONCBeOne Medicines
OVIDOvid Therapeutics
ASNDAscendis Pharma
QNCXQuince Therapeutics
EHCEncompass Health
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ocular Therapeutix

3 Months
Jonathan WollebenCitizens JMP
Success Rate
17/27 ratings generated profit
63%
Average Return
+15.94%
Copying Jonathan Wolleben's trades and holding each position for 3 Months would result in 62.96% of your transactions generating a profit, with an average return of +15.94% per trade.
1 Year
Jonathan WollebenCitizens JMP
Success Rate
17/27 ratings generated profit
63%
Average Return
+43.62%
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 62.96% of your transactions generating a profit, with an average return of +43.62% per trade.
2 Years
Jonathan WollebenCitizens JMP
Success Rate
22/27 ratings generated profit
81%
Average Return
+95.21%
Copying Jonathan Wolleben's trades and holding each position for 2 Years would result in 81.48% of your transactions generating a profit, with an average return of +95.21% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0OT Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
16
14
19
15
14
Buy
4
2
3
4
4
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
20
16
22
19
18
In the current month, 0OT has received 18 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 0OT average Analyst price target in the past 3 months is 21.23.
Each month's total comprises the sum of three months' worth of ratings.

0OT Financial Forecast

0OT Earnings Forecast

Next quarter’s earnings estimate for 0OT is -CHF0.30 with a range of -CHF0.32 to -CHF0.27. The previous quarter’s EPS was -CHF0.29. 0OT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0OT has Performed in-line its overall industry.
Next quarter’s earnings estimate for 0OT is -CHF0.30 with a range of -CHF0.32 to -CHF0.27. The previous quarter’s EPS was -CHF0.29. 0OT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0OT has Performed in-line its overall industry.

0OT Sales Forecast

Next quarter’s sales forecast for 0OT is CHF11.88M with a range of CHF11.12M to CHF13.27M. The previous quarter’s sales results were CHF11.18M. 0OT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0OT has Performed in-line its overall industry.
Next quarter’s sales forecast for 0OT is CHF11.88M with a range of CHF11.12M to CHF13.27M. The previous quarter’s sales results were CHF11.18M. 0OT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0OT has Performed in-line its overall industry.

0OT Stock Forecast FAQ

What is CH:0OT’s average 12-month price target, according to analysts?
Based on analyst ratings, Ocular Therapeutix’s 12-month average price target is 21.23.
    What is CH:0OT’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:0OT, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Ocular Therapeutix a Buy, Sell or Hold?
        Ocular Therapeutix has a consensus rating of Strong Buy, which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.
          What is Ocular Therapeutix’s share price target?
          The average share price target for Ocular Therapeutix is 21.23. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is CHF25.74 ,and the lowest forecast is CHF14.95. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Ocular Therapeutix?
            Ocular Therapeutix’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
              How can I buy shares of Ocular Therapeutix?
              To buy shares of CH:0OT, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.